Literature DB >> 19733384

Large cell change of hepatocytes in chronic viral hepatitis represents a senescent-related lesion.

Hiroko Ikeda1, Motoko Sasaki, Yasunori Sato, Kenichi Harada, Yoh Zen, Takeshi Mitsui, Yasuni Nakanuma.   

Abstract

Large cell change involves the clustering of hepatocytes with hyperchromatism and cellular enlargement without an increase in the nuclear/cytoplasmic ratio. This study investigated whether large cell change in chronic viral hepatitis reflects cellular senescence because of morphological similarities between the 2 conditions. The expression of markers of senescence such as senescence-associated beta-galactosidase, senescence-associated heterochromatic foci, and p21, as well as markers of cell kinetics such as Ki-67, was examined in 26 frozen and 82 formalin-fixed liver specimens. Large cell change was frequently detected in chronic hepatitis B cases with advanced histologic staging, particularly those with hepatocellular carcinoma. Senescence-associated beta-galactosidase activity, senescence-associated heterochromatic foci, and p21 were frequently detected in areas of large cell change. Hepatocytes with large cell change showed no proliferative or apoptotic activity. The frequent expression of senescent features and the absence of proliferative or apoptotic activity suggest that large cell change represents senescence. The parallel increase in large cell change and hepatocellular carcinoma in chronic hepatitis B raises the possibility that cellular senescence develops as a safeguard against malignant transformation rather than as a precursor of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733384     DOI: 10.1016/j.humpath.2009.06.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration.

Authors:  Katharine M Irvine; Richard Skoien; Nilesh J Bokil; Michelle Melino; Gethin P Thomas; Dorothy Loo; Brian Gabrielli; Michelle M Hill; Matthew J Sweet; Andrew D Clouston; Elizabeth E Powell
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

2.  Association between mitochondrial and nuclear DNA damages and cellular senescence in the patients with biliary atresia undergoing Kasai portoenterostomy and liver transplantation.

Authors:  Yudai Nakajima; Yuto Yamazaki; Xin Gao; Masatoshi Hashimoto; Masaki Nio; Motoshi Wada; Fumiyoshi Fujishima; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2022-03-03       Impact factor: 2.309

Review 3.  Telomere dysfunction in ageing and age-related diseases.

Authors:  Francesca Rossiello; Diana Jurk; João F Passos; Fabrizio d'Adda di Fagagna
Journal:  Nat Cell Biol       Date:  2022-02-14       Impact factor: 28.213

Review 4.  MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: current status and future prospects.

Authors:  Yi Lin Jane Tan; Wei Ning Chen
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 5.  Latest developments in precancerous lesions of hepatocellular carcinoma.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Wen-Hong Wang; Jing Zhao
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 6.  Liver pathology of hepatitis C, beyond grading and staging of the disease.

Authors:  Sadhna Dhingra; Stephen C Ward; Swan N Thung
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

7.  Comparative histomorphological review of rat and human hepatocellular proliferative lesions.

Authors:  Bob Thoolen; Fiebo J W Ten Kate; Paul J van Diest; David E Malarkey; Susan A Elmore; Robert R Maronpot
Journal:  J Toxicol Pathol       Date:  2012-10-01       Impact factor: 1.628

Review 8.  Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.

Authors:  William Peverill; Lawrie W Powell; Richard Skoien
Journal:  Int J Mol Sci       Date:  2014-05-14       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.